Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Short Interest Update

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) was the target of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 1,832,700 shares, a decrease of 15.1% from the May 30th total of 2,159,300 shares. Based on an average daily trading volume, of 187,500 shares, the days-to-cover ratio is presently 9.8 days. Approximately 12.5% of the shares of the stock are sold short.

NASDAQ:ENTA traded down $1.98 during trading hours on Friday, reaching $84.83. 172,072 shares of the company were exchanged, compared to its average volume of 225,515. The firm has a market capitalization of $1.69 billion, a P/E ratio of 24.74 and a beta of 1.03. Enanta Pharmaceuticals has a 1-year low of $64.08 and a 1-year high of $127.20. The firm has a 50 day moving average of $89.05.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.29. The business had revenue of $39.60 million for the quarter, compared to the consensus estimate of $40.92 million. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. The firm’s quarterly revenue was down 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.61 earnings per share. Equities research analysts anticipate that Enanta Pharmaceuticals will post 1.9 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. Rhumbline Advisers lifted its holdings in Enanta Pharmaceuticals by 0.3% during the 1st quarter. Rhumbline Advisers now owns 46,898 shares of the biotechnology company’s stock valued at $4,480,000 after buying an additional 145 shares in the last quarter. Mason Street Advisors LLC raised its stake in shares of Enanta Pharmaceuticals by 3.5% during the 1st quarter. Mason Street Advisors LLC now owns 5,058 shares of the biotechnology company’s stock worth $483,000 after acquiring an additional 172 shares in the last quarter. Pearl River Capital LLC raised its stake in shares of Enanta Pharmaceuticals by 174.5% during the 1st quarter. Pearl River Capital LLC now owns 280 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 178 shares in the last quarter. New York State Common Retirement Fund raised its stake in shares of Enanta Pharmaceuticals by 0.6% during the 1st quarter. New York State Common Retirement Fund now owns 34,447 shares of the biotechnology company’s stock worth $3,290,000 after acquiring an additional 200 shares in the last quarter. Finally, Piedmont Investment Advisors Inc. raised its stake in shares of Enanta Pharmaceuticals by 6.1% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 3,992 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 230 shares in the last quarter. 89.49% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently issued reports on ENTA. Berenberg Bank set a €126.00 ($146.51) price target on Nemetschek and gave the stock a “neutral” rating in a research report on Tuesday, April 23rd. BidaskClub raised Zumiez from a “sell” rating to a “hold” rating in a research report on Saturday, June 22nd. Wolfe Research began coverage on Enanta Pharmaceuticals in a research report on Friday, May 24th. They set an “outperform” rating and a $117.00 price target on the stock. Finally, Zacks Investment Research raised Garrett Motion from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $111.20.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Featured Article: Balance Sheet

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit